SEC Company Response from ReShape Lifesciences Inc. (RSLS) (CIK 0001427570) (HIND) — Feb 27, 2020
ReShape Lifesciences Inc. (RSLS) (CIK 0001427570)
Date: Feb. 27, 2020 · CIK: 0001427570 · Accession: 0001427570-20-000022
AI Filing Summary & Sentiment
File numbers found in text: 333-236327
Letter
Securities and Exchange Commission Attention: Paul Fischer Obalon Therapeutics, Inc. Registration Statement on Form S-1 File No. 333-236327
Re:
Dear Mr. Fischer:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, the undersigned, Obalon Therapeutics, Inc., a Delaware corporation (the “Registrant”), hereby requests acceleration of the effective date of the Registration Statement referred to above so that it may become effective at 4:30 p.m. Eastern Standard Time on February 28, 2020, or as soon as practicable thereafter. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Latham & Watkins LLP, by calling B. Shayne Kennedy at (714) 755-8181.
Thank you for your assistance in this matter.
[Signature Page Follows]
Very truly yours,
OBALON THERAPEUTICS, INC., a
Show Raw Text
CORRESP 1 filename1.htm Document Obalon Therapeutics, Inc. 5421 Avenida Encinas, Suite F Carlsbad, CA 92008 February 27, 2020 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Attention: Paul Fischer Re: Obalon Therapeutics, Inc. Registration Statement on Form S-1 File No. 333-236327 Dear Mr. Fischer: Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, the undersigned, Obalon Therapeutics, Inc., a Delaware corporation (the “Registrant”), hereby requests acceleration of the effective date of the Registration Statement referred to above so that it may become effective at 4:30 p.m. Eastern Standard Time on February 28, 2020, or as soon as practicable thereafter. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Latham & Watkins LLP, by calling B. Shayne Kennedy at (714) 755-8181. Thank you for your assistance in this matter. [Signature Page Follows] Very truly yours, OBALON THERAPEUTICS, INC., a Delaware corporation By: /s/ William Plovanic Name: William Plovanic Title: President and Chief Executive Officer cc: B. Shayne Kennedy, Latham & Watkins LLP